Search
Displaying 191–200 of 715 for “retinitis clinical trial”
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
-
Research News
Research has suggested that DHA in your diet is good for preventing and treating cardiovascular diseases, neurological conditions, depression and a slew of other conditions and maladies, including those that affect the retina.
-
AGTC Reports Promising Interim Results for XLRP and Achromatopsia Gene Therapy Trials
Research NewsAGTC used Foundation’s My Retina Tracker registry to recruit patients for trials
-
FFB Provides Four Career Development Awards to Up-and-Coming Clinical Researchers
Research NewsEach recipient will receive a total of $375,000 over five years to help build an independent research program in addition to their clinical practices.
-
Eye on the Cure Podcast | Episode 48: Jami Kern, PhD
Eye on the CureJune 16, 2023. Jami Kern, PhD, chief clinical officer at Nacuity Pharmaceuticals, talks with host Ben Shaberman about NACA, the company’s emerging gene-agnostic therapy for Usher syndrome and retinitis pigmentosa in a Phase 2 clinical trial in Australia. Their conversation includes a discussion about oxidative stress, which NACA is designed to mitigate, and timing for the efficacy readout from the Phase 2 study.
-
Eye on the Cure Podcast | Episode 45: Henry Klassen, MD, PhD
Eye on the CureApril 28, 2023. Henry Klassen, MD, PhD, co-founder of jCyte and clinical researcher at UC Irvine, talks to host Ben Shaberman about jCyte’s clinical trial results and future plans for developing its cell-based therapy for preserving vision caused by retinitis pigmentosa, Usher syndrome, and related retinal conditions.
-
Research News
Patients have reported life-changing vision improvements after treatment in the Phase 3 LUMEOS trial.
-
A Eureka Moment for Paul Yang Boosts Advancement of Vision-Saving RP Drug
Research NewsHis latest Foundation grant is helping move the drug toward a clinical trial
-
ARVO 2018: World's Largest Show and Tell for Innovations in Eye Research
Research NewsMore than 11,000 eye researchers from around the world — including five intrepid members from FFB’s science team — will gather to participate in what is essentially a massive “show and tell” of the latest scientific advancements.
-
History Is Made: FDA Approves Spark's Vision-Restoring Gene Therapy
Research NewsKnown as LUXTURNA™ (voretigene neparvovec), the gene therapy restored vision in a clinical trial for people between the ages of 4 and 44 with Leber congenital amaurosis (LCA) caused by mutations in the gene RPE65.
%20(7).png)
